RxDoctor Payments Data

Gary Quartello, DPM

Foot Surgery · Berkeley Hts, NJNPI 1902804479

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Musculoskeletal Transplant Foundation Inc. at 50.8% of the total. Reporting peaked in 2020 at $1,693 and has fallen 60.5% since, to $668 in 2025. Among foot surgery clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,462in general payments, 2019–2025

Across 114 payments — averaging $39.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Musculoskeletal Transplant Foundation Inc.$2K
  • Smith+Nephew$469
  • Organogenesis Inc.$325
  • Kerecis Limited$273
  • Urgo Medical North America, LLC$159
  • Lifenet Health$155
  • plus $815 from 16 others

What the payments were for

  • Travel & lodging$391%
  • Food & beverage$4,42399%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,462 in reported general payments places this provider in the 90th percentile of 59 foot surgery providers in New Jersey.

See all foot surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$134,587
Medicare patients
472
Services billed
2,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.25$8,058
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$256
Doxycycline Hyclate30$218
Cefadroxil24$198
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$161
Terbinafine Hcl18$146
Mupirocin15$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$469$8,05825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 59 foot surgery providers in New Jersey.

Other foot surgery in Berkeley Hts

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →